Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995)

Pediatric Pulmonology

Volumn 28, Issue 3, 1999, Pages 159-166

  Frederiksen, Birgitte ^a,b   Koch, Christian ^a   Høiby, Niels ^a  

^a Mental Health Services CPH   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Aggressive treatment; Cohorting; Cross infection; Cystic fibrosis; Epidemiology; Incidence; Prevalence; Pseudomonas aeruginosa

Indexed keywords

CIPROFLOXACIN; COLISTIN;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; COMORBIDITY; CYSTIC FIBROSIS; DENMARK; GRAM NEGATIVE INFECTION; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; TREATMENT PLANNING;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHRONIC DISEASE; CROSS INFECTION; CYSTIC FIBROSIS; FEMALE; HUMANS; INCIDENCE; INFUSIONS, INTRAVENOUS; MALE; PATIENT ISOLATION; PREVALENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; REGRESSION ANALYSIS; RESPIRATORY TRACT INFECTIONS;

EID: 0032828524     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0496(199909)28:3<159::AID-PPUL1>3.0.CO;2-1     Document Type: Article

References (39)

1. Mearns MB, Hunt GH, Rushworth R. Bacterial flora of respiratory tract in patients with cystic fibrosis, 1950-1971. Arch Dis Child 1972;47:902-907.
2. Høiby N. Epidemiological investigations of the respiratory tract in patients with cystic fibrosis. Acta Pathol Microbiol Scand [B] 1974;82:541.
3. Cystic Fibrosis Foundation USA. Patient Registry 1995 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation USA; 1996.
4. Berger M. Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good? Clin Rev Allergy 1991;9: 119-142.
5. Høiby N. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. A survey (thesis). Acta Pathol Microbiol Scand [C] [Suppl] 1977;262:3-96.
6. Bauernfeind A, Bertele RM, Harms K, Horl G, Jungwirth R, Petermuller C, Przyklenk B, Weisslein-Pfister C. Qualitative and quantitative microbiological analysis of sputa of 102 patients with cystic fibrosis. Infection 1987;4:270-277.
7. Taccetti G, Campana S. Microbiologic data overview of Italian cystic fibrosis patients. Eur J Epidemiol 1997;13:323-327.
8. Kerem E, Corey M, Gold R, Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 1990;116: 714-719.
9. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a poor marker of survival in cystic fibrosis. Pediatr Pulmonol 1992;12:158-161.
10. Hudson VL, Wielinski CL, Regelman WE. Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two. J Pediatr 1993;122:854-860.
11. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993;122:1-9.
12. Høiby N. Antibiotic therapy for chronic infection of Pseudomonas in the lung. Annu Rev Med 1993;44:1-10.
13. Jensen T, Pedersen SS, Garne S, Heilmann C, Høiby N, Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987;19:831-838.
14. Jensen T, Pedersen SS, Nielsen CH, Høiby N, Koch C. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. J Antimicrob Chemother 1987;20:585-594.
15. Valerius NH, Koch C, Høiby N. Prevention of chronic Ps aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991;338:725-726.
16. Frederiksen B, Koch C, Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997;23:330-335.
17. Høiby N. Microbiology of cystic fibrosis. In: Hodson ME, Geddes DM, editors. Cystic fibrosis, 1st ed. London: Chapman & Hill Medical: 1991. p 75-98.
18. Høiby N. Epidemiological investigations of the respiratory tract in patients with cystic fibrosis. Acta Pathol Microbiol Scand [B] 1974;82:541-550.
19. Høiby N, Pedersen SS. Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients. Acta Paediatr Scand 1989;78:395-404.
20. Frederiksen B, Lanng S, Koch C, Høiby N. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 1996;21:153-158.
21. Kelly NM, Filzgerald MX, Tempany E, O'Boyle C, Falkiner FR, Keane CT. Does Pseudomonas cross-infection occur between cystic fibrosis patients? Lancet 1982;2:688-689.
22. Smith DL, Smith EG, Gumery LB, Stableforth DE, Dalla Costa LM, Pitt T. Epidemiology of Pseudomonas aeruginosa infection in cystic fibrosis and the use of strain genotyping. J Infect 1993; 26:325-331.
23. Pedersen SS, Koch C, Høiby N, Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 1986;17:505-516.
24. Tümmler B, Kooperman U, Grothues D, Weissbrodt H, Steinkamp G, von der Hardt H. Nosocomial acquisition of Pseudomonas aeruginosa by cystic fibrosis. J Clin Microbiol 1991;29:1265-1267.
25. Cheng K, Smyth RL, Gowan JR, Doherty C, Winstanley C, Denning N, Heaf DP, van Saene H, Hart CA. Spread of a beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996;348:639-642.
26. Farrell PM, Shen G, Spaingard M, Colby CE, Laxova A, Kosorok MR, Rock MJ, Mischler EH. Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis. Pediatrics 1997;100:1-9.
27. Grothues D, Kopman U, von der Hardt, Tümmler B. Genome fingerprinting of Pseudomonas aeruginosa indicates colonisation of cystic fibrosis siblings with closely related strains. J Clin Microbiol 1988;26:1973-1977.
28. Govan JR, Brown PH, Maddison J, Doherty CJ, Nelson JW, Dodd M, Greening AP, Webb AK. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993; 342:15-19.
29. Ojeniyi B, Steen Petersen U, Høiby N. Comparison of genome fingerprinting with conventional typing methods used on Pseudomonas aeruginosa isolated from cystic fibrosis patients. APMIS 1993;101:168-175.
30. Rhame FS. The ecology and epidemiology of P. aeruginosa. In: Sabath LD, editor. Pseudomonas aeruginosa, the organism, diseases it causes and their treatment. Bern: Hans Huber Publishers; 1980. p 31-51.
31. Jensen ET, Giwercman B, Ojeniyi B, Bangsborg JM, Hansen A, Koch A, Fiehn N-E, Høiby N. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis and the possible role of contamination by dental equipment. J Hosp Infect 1997;36:117-122.
32. Sharma GD, Tosi MF, Stern RC, Davis PB. Progression of pulmonary disease after disappearance of Pseudomonas in cystic fibrosis. Am J Respir Crit Care Med 1995;152:169-173.
33. Johansen HK, Kovesi TA, Koch C, Corey M, Høiby N, Levison H. Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen. Pediatr Pulmonol 1998;26:89-96.
34. Szaff M, Høiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983;72:651-657.
35. Ciofu O, Giwercman, Pedersen SS, Høiby N. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF center. AP-MIS 1994;102:674-680.
36. Koch C, Hjelt K, Pedersen SS, Jensen ET, Jensen T, Lanng S, Valerius NH, Pedersen M, Høiby N. Retrospective clinical study of hypersensitivity reactions to aztreonam and 6 other beta-lactam antibiotics in cystic fibrosis patients receiving multiple treatment courses. Reviews of Infectious Diseases [Suppl] 1991;13:608-611.
37. Pedersen SS, Jensen T, Osterhammel D, Osterhammel P. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrob Agents Chemother 1987;31: 594-599.
38. Pressler T, Jensen T, Koch C. Decreased tolerability to tobramycin in patients with CF and chronic P. aeruginosa infection after many years of intensive treatment [abstract]. Isr J Med Sci [Suppl] 1996;32:257.
39. Frederiksen B, Høiby N, Bingen E, Brahimi N. Epidemiology of Stenotrophomonas maltophilia at the Danish Cystic Fibrosis Centre [abstract]. Pediatr Pulmonol 1995;12:287.